$69.30
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Own Oracle For The AI Boom? PTC's Story Looks Cleaner
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
Overview
52-week range
$57
$91
37% of range
Avg surprise (last 3)
+381.8%
Avg reaction (last 2)
-7.0%
0% positive
Latest IV / EM
50%
EM ±7.8% · $70 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.92 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.03 | $-0.45 | +93.3% | -100.3% | -3.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.20 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.83 | $-1.07 | +22.4% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $10.04 | $-1.08 | +1,030% | — | -11.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.39 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.29 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.76 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.66 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.88 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | — | $211M | $179M | $1.18B | — | $197M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $149M | $45M | — | $3M | $-35M | $970M | — | $-55M |
| Net income | $83M | $-3M | — | $16M | $-65M | $867M | — | $-107M |
| EPS (diluted) | $0.92 | $-0.03 | — | $0.20 | $-0.83 | $10.04 | — | $-1.39 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M |
| Total current assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B |
| Total assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B |
| Long-term debt | $536M | — | — | — | $286M | $286M | $285M | $285M |
| Total liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B |
| Total equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B |